New drug BGB-B455 targets tough tumors in early trial

NCT ID NCT06803680

Recruiting now Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose, then checking how well the drug works against the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGB-B455
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have the CLDN6 protein.
What could go wrong: This is a very early Phase 1 trial with only 90 participants, so it is not yet known if BGB-B455 is safe or effective. Many early-stage drugs do not move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Adventhealth
RECRUITING

Celebration, Florida, 34747-4606, United States
Avera Cancer Institute
RECRUITING

Sioux Falls, South Dakota, 57105-2108, United States
Beijing Cancer Hospital
COMPLETED

Beijing, Beijing Municipality, 100142, China
Blacktown Cancer and Haematology Centre
RECRUITING

Blacktown, New South Wales, NSW 2148, Australia
Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109-4433, United States
Fudan University Shanghai Cancer Centerpudong
RECRUITING

Shanghai, Shanghai Municipality, 201321, China
Liverpool Hospital
RECRUITING

Liverpool, New South Wales, NSW 2170, Australia
Mater Cancer Care Centre
TERMINATED

South Brisbane, Queensland, QLD 4101, Australia
Next Oncology
RECRUITING

San Antonio, Texas, 78229-6028, United States
Shanxi Provincial Cancer Hospital
RECRUITING

Taiyuan, Shanxi, 030013, China
Sidney Kimmel Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19107-4307, United States
The First Affiliated Hospital of Nanchang University Branch Donghu
RECRUITING

Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.